Merck & Co. presented full data from a Phase III trial testing Keytruda (pembrolizumab) as perioperative treatment in stage III or IVA resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) that may support an additional indication for the anti-PD-1 agent on top of its current US Food and Drug Administration approval for metastatic or unresectable, recurrent HNSCC.
Key Takeaways
- Merck’s KEYNOTE-689 trial shows that perioperative Keytruda can reduce risk of event-free survival in stage III-IVA head and neck cancer compared to radiotherapy.
The data from the KEYNOTE-689 trial showing a 21.4-month greater duration of event-free survival (EFS) compared to standard of care...